bone cancer and pain palliation


Systemic treatment options for bone and soft tissue sarcomas remained unchanged until the 2000s. These cancers presented challenges in new drug development partly because of their rarity and heterogeneity. Many new molecular targeting drugs have been tried in the 2010s, and some were approved for bone and soft tissue sarcoma.

The skeleton is a potential metastatic target of many malignant tumors. Up to 85% of prostate and breast cancer patients may develop bone metastases causing severe pain syndromes in many of them. Radionuclide therapy is recommended for pain palliation. The therapy is repeatable, depending on cell counts. Clinical trials using Radium-223 and/or combinations of chemotherapy and radionuclides are aiming at a more curative approach.

Sources:  PubMed

bone cancer


 32P-Sodium Phosphate (bone pain palliation – polycythemia vera)

89Sr-Strontium Chloride (bone pain palliation)

153Sm-Lexidronam (EDTMP) (bone pain palliation)

153Sm-Oxabiphor (ETMP) (bone pain palliation)

177Lu-EDTMP (bone pain palliation)

186Re-Rhenium Etidronate (HEDP) (bone pain palliation)

188Re-Etidronate (HEDP) (pain palliation – RSO)

223Ra-Radium Dichloride (bone metastases, prostate cancer spread to the bones)


177mSn-DTPA (bone pain palliation agent – (Veterinary Nuclear medicine drug))

153Sm-DOTMP (CycloSAM) (Bone pain palliation)


What is Bone Cancer – American Cancer Society

Bone Cancer (Sarcoma of Bone) – Cancer.Net

Compassionate Use Program (CUP)

CUP enables patients with life-threatening diseases, such as advanced cancer, to resort to experimental treatments when standard anti-cancer solutions and access to clinical trials are not an option. Access to CUP programs depends on local regulations and can vary from one treatment to another.

Ask your referring physicians for more information regarding CUP.